Find your next paid study

Jonsson Comprehensive Cancer CenterNCT05256641

~$10 – $6,250

Phase 2

Oncoquest-L Vaccine in Patients With Previously Untreated Stage III or IV, Asymptomatic, Non-bulky Follicular Lymphoma

This Phase II trial studies the overall tumor response of vaccine therapy in patientswith previously untreated Stage III or IV, asymptomatic, non-bulky follicu…

Follicular Lymphoma

XEME Biopharma Inc.NCT02194751

B-cell Acute Lymphoblastic LeukemiaB Lineage Lymphoblastic Lymphoma

Use of Autologous Anti-CD22 CAR T Cells (CART22-65s) Co-administered With Humanized Anti-CD19 CAR T Cells (huCART19) in Children and Young Adults With Relapsed or Refractory B-ALL

This study will evaluate the safety and efficacy of administering two CAR T cell products, huCART19 and CART22-65s, in children with advanced B cell Acute Lymp…

Stephan Grupp MD PhDNCT05674175

~$10 – $7,500

Observational

Implanted Loop Recorders (ILR) for the Detection and Management of Arrhythmia in Patients Treated With Bruton Tyrosine Kinase (BTK) Inhibitors

This study will enroll patients initiating Bruton Tyrosine Kinase (BTK) inhibitors without history of documented arrhythmia while on therapy using the Medtroni…

Atrial FibrillationSupraventricular ArrhythmiaVentricular Arrhythmias and Cardiac Arrest+2 more

Northwell HealthNCT05643235

~$10 – $7,500

Integrated Molecular and Clinical Profiling of Transformed Splenic Marginal Zone Lymphoma

Histological transformation in Splenic Marginal Zone Lymphoma (t-SMZL) represents an unmet clinical and biological need, invariably associated with poor progno…

Transformed Splenic Marginal Zone Lymphoma

International Extranodal Lymphoma Study Group (IELSG)NCT06712459

~$10 – $1,125

Ovarian Cancer, EpithelialGastric CancerGastroEsophageal Junction (GEJ) Cancer+11 more

A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage Lymphoma Proto-oncogene (CBL-B) Inhibitor, in Adults With Advanced Malignancies, With Phase 1b Expansion in Select Tumor Types

This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients wit…

Leukemia/LymphomaCutaneous T Cell LymphomaATLL

Nurix Therapeutics, Inc.

Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab

This is a non-interventional cohort study evaluating non-relapse mortality and toxicities in patients with CTCL or ATLL treated with mogamulizumab pre- or post…

Kyowa Kirin, Inc.NCT04014374

~$10 – $1,050

Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL)

A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL)

PeproMene Bio, Inc.NCT05370430

Phase 2

A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma

The purpose of this study is to see if the combination of rituximab and venetoclax is effective in treating participants with untreated Marginal Zone Lymphoma …

LymphomaMarginal Zone LymphomaMZL

Gottfried von Keudell, MD PhDNCT06510309

~$10 – $7,500

Acute Myeloid LeukemiaAcute Lymphoblastic LeukemiaHodgkin Lymphoma+8 more

TCR-αβ+ and CD19+ Depleted KIR/KIR Ligand-mismatched Haploidentical Hematopoietic Stem Cell Transplant and Zoledronate for Pediatric Relapsed/Refractory Hematologic Malignancies and High Risk Solid Tumors

This phase I trial studies the safety of transplantation with a haploidentical donor peripheral blood stem cell graft depleted of TCRαβ+ cells and CD19+ cells …

University of Wisconsin, MadisonNCT02508038

~$10 – $6,250

Non Hodgkin LymphomaRichter TransformationMultiple Myeloma+10 more

A Phase 1/1b Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of LP-118 in Subjects With Relapsed or Refractory Hematological Malignancies

This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tole…

Newave Pharmaceutical IncNCT04771572

A Phase 1, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy of DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)

This study will treat patients with B-NHL who have relapsed, progressed, or were intolerant to systemic therapy progressed following prior therapy. This study …

Lymphoma, Non-Hodgkin